- Home
- TAC vs LNTH Comparison
TAC vs LNTH Comparison
Compare TAC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | LNTH |
|---|---|---|
| Founded | 1909 | 1956 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | TAC | LNTH |
|---|---|---|
| Price | $13.47 | $67.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $21.63 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 1.7M | 726.1K |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | ★ $1,783,342,546.00 | $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | N/A | $0.26 |
| P/E Ratio | ★ N/A | $28.12 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $7.82 | $47.25 |
| 52 Week High | $17.88 | $111.29 |
Technical Indicators
Market Signals| Indicator | TAC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 56.43 |
| Support Level | $13.02 | $63.45 |
| Resistance Level | $13.62 | $67.34 |
| Average True Range (ATR) | 0.55 | 2.16 |
| MACD | 0.08 | -0.12 |
| Stochastic Oscillator | 68.15 | 64.43 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.